RxDoctor Payments Data

Mika Zeeryp

Family · Murrells Inlet, SCNPI 1952067662

Payments from drug & device makers

$4,521in general payments, 2019–2025

Across 244 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$534
  • Johnson & Johnson$510
  • Xeris Pharmaceuticals, Inc.$204
  • QOL Medical, LLC$203
  • Ardelyx, Inc.$166
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,43798%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,521 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$68,758
Medicare patients
591
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide44$45,323
IbsrelaTenapanor Hcl11$31,285
TrulancePlecanatide13$19,558
Pantoprazole Sodium340$4,860
Dexlansoprazole DrDexlansoprazole12$3,373
Sucralfate23$2,758
Dicyclomine Hcl73$1,958
Famotidine118$1,942
Colestipol Hcl14$1,433
Omeprazole75$1,082
Esomeprazole Magnesium15$727
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$625
Ondansetron OdtOndansetron21$559
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$351
Lactulose17$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,270$45,32344 claims
Ardelyx, Inc.Ibsrela$166$31,28511 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$534$19,55813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →